Dimitra Koumaki: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece. ORCID
Sofia Maraki: Department of Medical Microbiology, University Hospital of Heraklion, 71110 Heraklion, Greece.
Georgios Evangelou: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece. ORCID
Vasiliki Koumaki: Department of Medical Microbiology, Medical School of Athens, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Goudi, 11527 Athens, Greece.
Stamatios Gregoriou: Department of Dermatology and Venereology, Andreas Sygros Hospital, Medical School of Athens, National and Kapodistrian University of Athens, I. Dragoumi 5, 16121 Athens, Greece. ORCID
Stamatoula Kouloumvakou: 2nd Department of Internal Medicine, Sismanoglio General Hospital, Sismanogliou 37, 15126 Athens, Greece. ORCID
Danae Petrou: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Evangelia Rovithi: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Kyriaki Zografaki: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece. ORCID
Aikaterini Doxastaki: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Petros Ioannou: Department of Internal Medicine, University Hospital of Heraklion, 71500 Heraklion, Greece. ORCID
Ioanna Gkiaouraki: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Antonios Rogdakis: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Viktoria Eirini Mavromanolaki: Department of Pediatrics, Agios Nikolaos General Hospital, 72100 Agios Nikolaos, Greece.
Konstantinos Krasagakis: Dermatology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
Methicillin-resistant (MRSA) poses significant treatment challenges, particularly in community settings. Limited data are available on -associated infected dermatoses (ID) in outpatient dermatology clinics. This study examines the clinical characteristics, microbiological profiles, resistance patterns, and treatment outcomes of dermatoses caused by . Between January 2023 and January 2025, consecutive patients with confirmed -associated SD were recruited in a dermatology clinic in Heraklion, Greece. Demographic, clinical, and treatment data were collected. Skin swabs underwent bacterial culture and antimicrobial susceptibility testing following CLSI guidelines. Statistical analyses evaluated associations between clinical and microbiological findings. Sixty-eight patients were included, 54.4% of whom were male, with a mean age of 46.7 years (�� SD 25.1). MRSA was identified in 22.1% of cases and was significantly associated with female gender ( = 0.014). The most common diagnoses were eczema (35.3%) and folliculitis (19.1%). Oxacillin-resistant patients were more likely to receive systemic therapy ( = 0.039). Resistance rates were highest for benzylpenicillin (81.8%), levofloxacin (54.9%), and erythromycin (39.4%). Resistance rates for fusidic acid, clindamycin, mupirocin, and tetracycline were 38.2%, 20.6%, 16.9%, and 10.3%, respectively. Other pathogens, including and , were isolated in 27.9% of cases. This study highlights the high prevalence of MRSA in outpatient dermatology settings, emphasizing the need for local antimicrobial resistance surveillance to guide treatment strategies and improve outcomes in superinfected dermatoses.
